Company Name: Salspera, Inc.
Date of Prospectus: March 4, 2026

Salspera, Inc. IPO: Advanced Oncology Biotech Targets Solid Tumors with Breakthrough Bacterial Immunotherapy

IPO Snapshot: Salspera Enters the Market with Solid Tumor Innovation

Salspera, Inc. (“TKVA” – Nasdaq) is launching its initial public offering, aiming to raise fresh capital to advance its clinical-stage pipeline targeting difficult-to-treat solid tumors, especially pancreatic cancer, osteosarcoma, and metastatic colorectal cancer. The offering is 100% primary shares, highlighting a clear growth and R&D funding focus.

Use of proceeds: Primarily to fund a pivotal Phase 3 study for Saltikva (bacteria-based immunotherapy for pancreatic cancer), with the remainder supporting Phase 2 programs in osteosarcoma and colorectal cancer, as well as general corporate purposes and working capital. The structure and allocation clearly signal a growth-driven capital raise with a focus on advancing late-stage clinical assets and pipeline expansion[[2]].

Deal Structure and Key Parties Supporting the Listing

Kingswood Capital Partners, LLC is the sole bookrunner, responsible for syndication and distribution. The offering includes a 45-day over-allotment option for 850,000 shares, providing stabilization potential.
A strict 180-day lock-up applies to the company’s officers, directors, and substantially all capital stock holders, aligning management and long-term investor interests[[2]].

Company Overview: Transforming Oncology with Live Biopharmaceuticals

Salspera is a clinical-stage biotechnology company focused on bacterial immunotherapy for solid tumors. Its lead program, Saltikva, leverages engineered, orally administered Salmonella typhimurium to deliver human IL-2 directly into tumors, stimulating the immune system to target cancer cells. The unique approach allows for:

• Highly targeted IL-2 delivery with minimized systemic toxicity
• Combination therapy potential – Saltikva can encode multiple peptides or be used with other salmonella strains expressing different immunomodulatory molecules
• Oral, non-toxic immunotherapy alternative to traditional IL-2 treatments[[11]]

Revenue Streams & Monetization: Salspera is pre-commercial and focused on clinical development. The current pipeline includes:

• Saltikva (Pancreatic Cancer, lead asset) – poised for Phase 3 after promising Phase 2 data
• Phase 2-ready programs in osteosarcoma and metastatic colorectal cancer[[16]]

Industry Position and Market Opportunity

Salspera operates in the fast-growing Live Biopharmaceutical (LBP) Therapeutics arena, with the landscape expanding from a handful of companies in 2017 to over 20 by 2025. Based on recent publications, Saltikva is described as the most advanced program in its field[[10]].
Market Size: Pancreatic cancer alone sees approximately 64,000 new cases annually in the U.S. and over 500,000 globally. Osteosarcoma affects roughly 1,000 new U.S. patients and 26,000 globally per year. These figures underscore a significant unmet need and large addressable market[[16]].

Financial Health and Capitalization

Salspera has been privately funded through completion of Phase 2 trials. Proceeds from the IPO will finance:

• Phase 3 trial in pancreatic cancer
• Phase 2 trial in osteosarcoma
• Phase 2 trial in metastatic colorectal cancer

The focus on late-stage clinical investment and pipeline expansion signals disciplined capital allocation targeting high-impact inflection points[[30]].

Experienced Leadership and Advisory Boards

Management and Board:

• Eddie Moradian, PhD – CEO, Co-Founder: Founded/co-founded 10 biotech firms over 30 years, extensive operational and early-stage drug development experience, PhD from ETH Zurich
• Daniel Saltzman, MD, PhD – CMO, Co-Founder: Originator of Salspera’s technology, Chief of Pediatric Surgery at University of Minnesota
• Board includes Chuck Garner (Lead Director), Luisa Ingargiola, David Schaffer, PhD[[7,8]]

Scientific Advisory Board: Features global leaders such as G. Batist (McGill), Mitesh J. Borad (Mayo Clinic), Richard L. Schilsky (ASCO TAPUR Study), Barry P. Sleckman (O’Neal Comprehensive Cancer Center), and Talia Golan (Sheba Medical Center)[[9]].

Clinical Pipeline and Efficacy Data

Saltikva: Transformative Clinical Data in Pancreatic Cancer

• Phase 2 (n=34): Saltikva + FOLFIRINOX in Stage IV pancreatic cancer
• Median Progression Free Survival (mPFS): 15.0 months (vs. 5.8 months historic control, 158% improvement, p<0.001)
• Median Overall Survival (mOS): 20.3 months (vs. 11.5 months control, 77% improvement, p<0.05)
• Overall Response Rate (ORR): 70%
• No serious adverse events attributed to Saltikva; all Grade 3/4 SAEs were due to standard chemotherapy[[21,22,23,24]]
• Saltikva demonstrated statistically significant, robust efficacy signals and an outstanding safety profile compared to contemporary agents[[24,25]]

Osteosarcoma Program: Canine studies (modeling human disease) showed 22% overall survival at 500 days vs. 0% for standard of care, supporting the rationale for human clinical translation[[28,29]].

Sector Trends, Timing, and Market Environment

Bacterial cancer therapy is rapidly emerging as a central part of the oncology therapeutic paradigm, with significant growth in the number of companies and programs worldwide. The timing of the IPO leverages recent strong clinical data and regulatory momentum, including:

• FDA Orphan Drug Designation and Fast Track for Saltikva in pancreatic cancer (May 2022)
• Phase 3 study design agreed with FDA, eligible for Accelerated Approval and Priority Review[[16]]

The company’s U.S., EU, Australia, and Israel trial sites position it for international relevance. The offering is scheduled for the week of March 23, 2026, targeting a market receptive to oncology innovation[[2,26]].

Risk Factors and Strategic Growth Plans

Key Risks:

• Regulatory uncertainty: Saltikva and other candidates are not yet approved; ongoing dependence on successful clinical outcomes and regulatory clearance
• Concentration risk: Lead asset Saltikva is the primary value driver
• Financing risk: Future capital needs may arise, as commercial revenue is not yet generated
• Dependence on key personnel and third-party manufacturers
• Market adoption risk: Clinical acceptance and payer coverage for a novel modality[[5]]

Growth Strategy:

• Advance Saltikva through pivotal Phase 3 trial for pancreatic cancer
• Initiate Phase 2 trials in osteosarcoma and metastatic colorectal cancer
• Explore out-licensing opportunities and co-development partnerships
• Pursue accelerated and priority review pathways[[16,26,30]]

Ownership Structure and Lock-up Details

Pre- and post-IPO shareholding structure details are not explicitly disclosed; however, the prospectus confirms a 180-day lock-up on officers, directors, and substantially all capital stock holders, aligning long-term interests and restricting immediate secondary market supply[[2]].

Valuation and Peer Comparison

While peer financial metrics (P/E, P/B, EV/EBITDA, ROE, etc.) are not disclosed, the prospectus does provide a comparative snapshot of recent and ongoing clinical programs among peer companies in metastatic pancreatic cancer.

Saltikva exhibits best-in-class efficacy signals compared to peers in the same indication and line of therapy, based on ORR, mPFS, and mOS. This clinical differentiation could drive investor interest and premium pricing upon listing[[19,25]].

Investor Participation, Allotment, and Book Quality

No named cornerstone, anchor, or institutional allocations are disclosed. No data on retail/institutional oversubscription or pre-listing disposals are provided. The presence of a single bookrunner and structured lock-up suggests a disciplined approach to market stabilization and float management. The deal’s structure, with a 45-day over-allotment, may support listing-day performance, especially if bookbuild demand is strong[[2]].

Recent Developments and Sector Outlook

Recent milestones for Salspera include:

• Completion of Phase 2 study in Stage IV pancreatic cancer with exceptional efficacy and safety results
• Receipt of FDA Orphan Drug and Fast Track Designations
• Phase 3 study protocol alignment with FDA
• Expansion into osteosarcoma and colorectal cancer Phase 2 studies[[16,21]]

The company has also highlighted positive patient testimonials and robust preclinical results in both human and canine models, supporting a broad solid tumor strategy[[27,28,29]].

Listing Outlook: Investor Assessment and First-Day Prospects

Based strictly on the prospectus: Salspera’s IPO is underpinned by compelling clinical data, a differentiated pipeline, credible management, and a clear growth funding plan. The significant improvement in survival outcomes for pancreatic cancer positions the company for sector leadership in bacterial immunotherapy. The deal’s structure (100% primary, strong lockups, and bookrunner support) is likely to support first-day trading. Provided that clinical execution continues, the IPO appears attractive for growth-focused and biotech investors seeking exposure to a high-potential, late-stage oncology asset. The likely first-day trading range should remain at or above the offer price, subject to market conditions and demand.

Accessing the Prospectus and Application Process

Full offering details, including the prospectus, can be obtained at: www.sec.gov

Bookrunner contact for prospectus requests and syndicate allocation: Kingswood Capital Partners, LLC, Attention: Syndicate, 126 East 56th Street Floor 22, New York, NY 10022, Tel: 212-487-1080, Email: [email protected]